Benzene Contamination in Sunscreen Products in the US
Benzene is a chemical that is widely used in some industries. However, benzene is a known human carcinogen and therefore its use or trace presence in cosmetics and personal care products is not allowed. In the U.S., a recent report has identified 78 sun care products contaminated with benzene, requiring their recall by the FDA in order to protect consumers.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


A testing and consumer protection organization located in the U.S. has detected high levels of Benzene in several brands and batches of sunscreen (classified as drug products by the FDA) and after-sun products (generally regulated as cosmetics by the FDA). The company analysed 294 unique batches from 69 different companies, observing significant variability from batch to batch, even within a single company. According to the study, 27% of the samples tested, representing a total of 78 sun care products, contained benzene. Some batches contained up to three times the conditionally restricted FDA concentration limit (2 ppm). Benzene was detected in sprays, gels, and lotions (with both chemical and mineral-based formulations).

Since benzene is one of the most studied and concerning human carcinogens known to science, with numerous studies showing its association with blood cancers in humans even at trace levels of parts per million and below, the presence of this carcinogen in products widely recommended for the prevention of skin cancer and that are regularly used by adults and children is very troubling.

Study authors are currently pushing for a recall of all the contaminated batches and asking the FDA to better define limits for Benzene contamination in drug and cosmetic products. In March 2021, a petition had already been issued (2021 Citizen Petition) on benzene contamination in hand sanitizer and there were several recalls of contaminated hand sanitizer products.

Since the report was published, the U.S. Food and Drug Administration started investigating the root cause of benzene found these sunscreen products. Some brands already started voluntarily recalling the products and advised consumers to stop using them. Despite this, the agency continued advising patients to use broad spectrum sunscreens with SPF 15 or higher in conjunction with other sun protective measures.


Benzene is a chemical that can be found in nature and manufactured products. It is used as a chemical intermediate to make several industrial chemicals. Smaller amounts are often used in chemical laboratories as solvent and reagent. Moreover, benzene is used as a constituent in motor fuels, in the extraction of oils from seeds and nuts, in the manufacture of detergents, explosives and pharmaceuticals, for example. Benzene is used as a starting material for synthetic fragrances. Trace levels of benzene may be found in cigarette smoke, gasoline, glues, adhesives, cleaning products, and paint strippers.

Individuals that work in industries that manufacture or use benzene may be exposed to highest levels of this compound, being occupational exposure one of the main concerns of the toxicity of benzene. Tobacco smoke also contains benzene and represents one of the most significant sources of exposure. People may also be exposed to benzene by consuming contaminated water.

Benzene is rapidly absorbed through skin from both liquid and vapour phases, as shown in human and experimental studies. Although dermal absorption is minimal when compared with inhalation or oral absorption because it rapidly volatilizes in the skin, it still has toxic effects associated to dermal exposure. Benzene was irritating to the mucous membranes of eyes, mouth, respiratory tract and skin in rodents.

Human exposure to benzene occurs primarily via inhalation in the workplace, from gasoline vapors, tobacco smoke and automotive emissions. People exposed to the chemical exhibit bone marrow depression (evidenced by anemia), leukopenia and/or thrombocytopenia. Inhalation of exposure can cause neurological symptoms like drowsiness, dizziness, headaches and unconsciousness in humans. Liquids and vapours containing benzene have shown to irritate the skin, eyes and upper respiratory tract. Benzene causes both structural and numerical chromosomal aberration in humans.

Exposure to benzene can cause acute nonlymphocytic leukemia and other blood disorders (preleukemia and aplastic anemia), as shown in human epidemiologic studies of highly exposed occupational cohorts. Studies in humans and experimental animals have demonstrated that this compound may also cause hematotoxicity (changes in blood and bone marrow).

Benzene is a “known human carcinogen by all routes of exposure”, according to the U.S. Environmental Protection Agency (EPA). Benzene is defined as a carcinogen by the National Institute for Occupational Safety and Health (NIOSH) which lists “inhalation, skin absorption, ingestion, skin and/or eye contact” as exposure routes. The International Agency for Research on Cancer (IARC) classifies Benzene as a Group 1 human carcinogen.


According to the European Regulation (EC) No 1223/2009 on cosmetic products, Benzene is included in the list of substances prohibited in cosmetic products (Annex II). This means that in the European Union, Benzene is not allowed in cosmetics and personal care products, as it is classified as a Carcinogen Category 1A.

The U.S. Food and Drug Administration (FDA) lists Benzene as a Class 1 solvent “that should not be employed in the manufacture of drug substance. However, if their use is unavoidable in order to produce a drug product with a significant therapeutic advance, then their levels should be restricted”. For these particular situations, Benzene is restricted to 2 parts per million (ppm).

Because of its toxicity, the FDA has determined that Benzene can not be used in pharmaceutical production. However, there is no exposure limit established for Benzene, and the 2ppm limit only applies in special circumstances.

If you wish to get more information on Benzene or other subjects related to the EU Cosmetics Regulation, do not hesitate to contact us at


  1. Valisure Detects Benzene in Suscreen. May 25, 2021. Valisure News. Available from:
  2. Toxicological Review of Benzene (Noncancer Effects) – (CAS No. 71-43-2). In Support of Summary Information on the Integrated Risk Information System (IRIS). October 2002. Available from:
  3. Opinion on the results of the Risk Assessment of: Benzene. Human Health Part. CAS Nº: 71-43-2. EINECS Nº: 200-753-7. Scientific Committee on Toxicity, Ecotoxicity and the Environment (CSTEE). 2003. Available from:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »